TOSHIBA
23.2.2024 17:44:33 CET | Business Wire | Press release
At EuroCIS 2024, Toshiba Global Commerce Solutions showcases how retailers can “Create Beyond what’s Possible” to transform retail operations and customer experiences with its innovative solutions portfolio (booth in hall 9 #B42). The international trade fair will take place on February 27-29 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223284358/en/
At EuroCIS 2024, Toshiba Global Commerce Solutions will empower retailers to transform their operations and customer experiences with innovative solutions and services. (Photo: Business Wire)
“Our unified commerce and self-service solutions help retailers create shopping experiences that go beyond consumer expectations,” says Meike Marquardt, Head of Marketing for Europe, Toshiba Global Commerce Solutions. “With Toshiba Global Commerce Solutions as a trusted partner, retailers have the power to adapt effortlessly to the rapidly changing business needs of the industry and to think beyond their limitations.”
During EuroCIS, retailers can experience how Toshiba’s end-to-end solutions backed with the latest innovative technologies empower retailers to transform business with enhanced store insights, operations, and customer experiences. Guests at Toshiba’s booth will encounter self-service solutions that leverage A.I., computer vision, and edge computing technologies that reduce friction and address critical industry challenges like shrink. Toshiba will also feature the Retail Command Center showcasing Connected Services with A.I.-powered analytics that take the store support services model from reactive to proactive. Featured mobile and unified commerce solutions will demonstrate how retailers can evolve with their customers across multiple touchpoints. Solutions in Toshiba’s booth are all part of a composable and modular portfolio that allows retailers to take control of their transformation journey and accelerate change in the way that best suits their business needs.
Self-Service solutions leverage A.I., computer vision and edge computing
- Toshiba’s Vision Kiosk bypasses barcodes completely by automatically identifying and validating items, typically in convenience, pharmacy and specialty stores. The computer vision self-service kiosk offers the ability to buy items quickly and easily using contactless and biometric payments, powered by PopID.
- The TCx® SMART Self Checkout offers multiple customisation options including wall-mounted and freestanding solutions, designed to meet changing self-service expectations across retail segments including grocery, specialty and convenience.
- Toshiba’s Self Checkout System 7 integrates edge computing cameras to minimize shrink while providing consumers enhanced checkout experiences and reduced friction. For produce recognition the TCx EDGEcam leverages A.I. and computer vision integrated with Intel technology to identify produce accurately and fast. Based on retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout. Furthermore, the TCx EDGEcam+ utilizes Qualcomm® System-on-Chip (SoC) technology to enhance loss prevention capabilities, ensuring comprehensive security measures.
A.I.-enabled Connected Services powers operational efficiency in stores
Toshiba’s recently opened Command Center in Brussels is ready to deliver A.I.-enabled Connected Services for retailers. At EuroCIS, retailers will experience the Retail Command Center in real life, showing how A.I.-enabled analytics can identify failure patterns of hardware components and software processes, enabling retailers to drive technology management decisions instantly, changing the store support model from reactive to proactive, minimizing downtime, and lost revenues.
Unified Commerce brings agility to mobile and in-store touchpoints
Modern consumer shopping journeys are constantly evolving, moving from digital to physical, mobile to in-store, and vice-versa. Mobile solutions are a given for shoppers and are essential for in-store staff. Toshiba’s unified commerce makes this easy, leveraging a unified single basket architecture across multiple touchpoints.
Composable and modular software solutions enable retailers to accelerate change
Retailers looking to transform their business and to adopt innovative technologies to meet their consumer expectations can consider solutions to replace a complete platform, as well as composable technologies when wanting to introduce innovative applications step by step. Everything is available in a software-as-a-service (SaaS) model to ease affordability and speed of deployment.
Toshiba will speak on both the Connected Retail & Retail Technology Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 27 at 12:40 - 1:00 pm on the Connected Retail Stage
How Remote Monitoring can help the retailer to be ahead of the game
Jules Harms, Director Professional Services, Toshiba Global Commerce Solutions
February 28 at 3:00 - 3:20 pm on the Retail Technology Stage
Ground to Cloud – Driving Transformation in Retail
Mike Mooney, Vice President of Solutions, Toshiba Global Commerce Solutions
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223284358/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
